These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Expression of 17β-hydroxysteroid dehydrogenase type 1 in gastric cancer. Frycz BA; Murawa D; Wysocki-Borejsza M; Marciniak R; Murawa P; Drews M; Jagodziński PP Biomed Pharmacother; 2013 Sep; 67(7):651-7. PubMed ID: 23916544 [TBL] [Abstract][Full Text] [Related]
3. Decreased expression of connective tissue growth factor in non-small cell lung cancer is associated with clinicopathological variables and can be restored by epigenetic modifiers. Drzewiecka H; Gałęcki B; Jarmołowska-Jurczyszyn D; Kluk A; Dyszkiewicz W; Jagodziński PP J Cancer Res Clin Oncol; 2016 Sep; 142(9):1927-46. PubMed ID: 27393180 [TBL] [Abstract][Full Text] [Related]
4. Conversion of estrone to 17-beta-estradiol in human non-small-cell lung cancer cells in vitro. Drzewiecka H; Jagodzinski PP Biomed Pharmacother; 2012 Oct; 66(7):530-4. PubMed ID: 22705334 [TBL] [Abstract][Full Text] [Related]
5. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis. Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757 [TBL] [Abstract][Full Text] [Related]
6. Decreased expression of 17β-hydroxysteroid dehydrogenase type 1 is associated with DNA hypermethylation in colorectal cancer located in the proximal colon. Rawłuszko AA; Horbacka K; Krokowicz P; Jagodziński PP BMC Cancer; 2011 Dec; 11():522. PubMed ID: 22176788 [TBL] [Abstract][Full Text] [Related]
8. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Soria JC; Lee HY; Lee JI; Wang L; Issa JP; Kemp BL; Liu DD; Kurie JM; Mao L; Khuri FR Clin Cancer Res; 2002 May; 8(5):1178-84. PubMed ID: 12006535 [TBL] [Abstract][Full Text] [Related]
9. Altered expression of 17‑β‑hydroxysteroid dehydrogenase type 2 and its prognostic significance in non‑small cell lung cancer. Drzewiecka H; Jarmołowska-Jurczyszyn D; Kluk A; Gałęcki B; Dyszkiewicz W; Jagodziński PP Int J Oncol; 2020 Jun; 56(6):1352-1372. PubMed ID: 32236582 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results. Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205 [TBL] [Abstract][Full Text] [Related]
11. Significance of methylation status and the expression of RECK mRNA in lung tissue of patients with NSCLC. Pesta M; Kulda V; Topolcan O; Safranek J; Vrzalova J; Cerny R; Holubec L Anticancer Res; 2009 Nov; 29(11):4535-9. PubMed ID: 20032402 [TBL] [Abstract][Full Text] [Related]
12. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823 [TBL] [Abstract][Full Text] [Related]
13. Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor. Verma MK; Miki Y; Abe K; Suzuki T; Niikawa H; Suzuki S; Kondo T; Sasano H J Transl Med; 2013 Jul; 11():167. PubMed ID: 23837683 [TBL] [Abstract][Full Text] [Related]
14. [Effects of 5-Aza-2-deoxycytidine on DNA methylation of anti-oncogenes in non-small cell lung cancer cells]. Fang HL; Yu ZC; Zhu HB; Jin YT Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):658-63. PubMed ID: 23159077 [TBL] [Abstract][Full Text] [Related]
15. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Ceppi P; Mudduluru G; Kumarswamy R; Rapa I; Scagliotti GV; Papotti M; Allgayer H Mol Cancer Res; 2010 Sep; 8(9):1207-16. PubMed ID: 20696752 [TBL] [Abstract][Full Text] [Related]
16. RNF111/Arkadia is regulated by DNA methylation and affects TGF-β/Smad signaling associated invasion in NSCLC cells. Chen H; Yang T; Lei Z; Wang L; Yang H; Tong X; Yang WT; Zhao J; Gu Y; Chen Y; Zhang HT Lung Cancer; 2015 Oct; 90(1):32-40. PubMed ID: 26238425 [TBL] [Abstract][Full Text] [Related]
17. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Zhang Y; Miao Y; Yi J; Wang R; Chen L Clin Lung Cancer; 2010 Jul; 11(4):264-70. PubMed ID: 20630829 [TBL] [Abstract][Full Text] [Related]
18. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer. Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719 [TBL] [Abstract][Full Text] [Related]
19. The EPHB6 receptor tyrosine kinase is a metastasis suppressor that is frequently silenced by promoter DNA hypermethylation in non-small cell lung cancer. Yu J; Bulk E; Ji P; Hascher A; Tang M; Metzger R; Marra A; Serve H; Berdel WE; Wiewroth R; Koschmieder S; Müller-Tidow C Clin Cancer Res; 2010 Apr; 16(8):2275-83. PubMed ID: 20371680 [TBL] [Abstract][Full Text] [Related]
20. TGF-β-activated SMAD3/4 complex transcriptionally upregulates N-cadherin expression in non-small cell lung cancer. Yang H; Wang L; Zhao J; Chen Y; Lei Z; Liu X; Xia W; Guo L; Zhang HT Lung Cancer; 2015 Mar; 87(3):249-57. PubMed ID: 25595426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]